All In Biotech

Drug Trial Radar · NCT04768972

FUSION: A Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of ION363 in Amyotrophic Lateral Sclerosis Participants With Fused in Sarcoma Mutations (FUS-ALS)

A Phase 1-3 Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Intrathecally Administered ION363 in Amyotrophic Lateral Sclerosis Patients With Fused in Sarcoma Mutations (FUS-ALS)

Last checked: Nov 19, 2026Latest source record: Jul 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

89

Actual

Start

Jun 14, 2021

Primary completion

Jun 17, 2026

Study completion Mar 2028

Sponsor

Lead sponsor
Ionis Pharmaceuticals, Inc.Ionis Pharmaceuticals (IONS)
Sponsor type
Industry
First posted
Feb 24, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 10 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary purpose of this study is to evaluate the efficacy of ION363 on clinical function and survival in carriers of fused in sarcoma mutations with amyotrophic lateral sclerosis (FUS-ALS).

Conditions

  • Amyotrophic Lateral Sclerosis

Interventions

  • ION363Drug

    ION363 will be administered by IT bolus injection.

  • PlaceboDrug

    Placebo will be administered by IT bolus injection.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from Baseline (Day 1) through Study Day 505 in Part 1 in functional impairmentTime frame: Baseline, Day 505 in Part 1

Locations

25 sites in 16 countries. Site status is shown where the registry gives one.

  • University of California San Diego

    La Jolla, California

  • Stanford University Medical Center

    Palo Alto, California

  • Johns Hopkins University

    Baltimore, Maryland

  • Massachusetts General Hospital

    Boston, Massachusetts

  • Washington University School of Medicine

    St Louis, Missouri

  • Columbia University Medical Center

    New York, New York

  • The Ohio State University Wexner Medical Center

    Columbus, Ohio

  • University of Utah

    Salt Lake City, Utah

  • UZ Leuven

    Leuven, VL-Brabant, Belgium

  • PSEG Centro de Pesquisa Clinica S.A.

    São Paulo, Brazil

  • Montreal Neurological Institute

    Montreal, Quebec, Canada

  • Universitaetsmedizin Rostock

    Rostock, Germany

  • Universitätsklinikum Ulm

    Ulm, Germany

  • St. James Hospital

    Dublin, Ireland

  • Citta della Salute e della Scienza di Torino - Ospedale le Molinette

    Torino, Italy

  • Toho University Omori Medical Center

    Tokyo, Japan

  • Universitair Medisch Centrum Utrecht

    Utrecht, Netherlands

  • Linden spólka z ograniczona odpowiedzialnoscia spólka komandytow

    Krakow, Poland

  • Seoul National University Hospital

    Seoul, South Korea

  • Hanyang University Seoul Hospital

    Seoul, South Korea

  • Hospital Universitari de Bellvitge

    Barcelona, Spain

  • University Hospital of Umea

    Umeå, Sweden

  • Kantonsspital St. Gallen

    Sankt Gallen, Switzerland

  • Taipei Veterans General Hospital (VGHTP)

    Taipei, Taiwan

  • King's College Hospital

    London, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.